SEC Company Response from RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643) (RLMD) — Oct 17, 2019
RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643)
Date: Oct. 17, 2019 · CIK: 0001553643 · Accession: 0001213900-19-020563
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233228
Referenced dates: October 16, 2019
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Re: Relmada Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-l Filed October 11, 2019 File No. 333-233228
Dear Ms. Aldave:
We are in receipt of your comment letter dated October 16, 2019 regarding the above referenced filing. As requested in your letter, we have provided responses to the questions raised by the staff. For your convenience, the matters are listed below, followed by Relmada Therapeutics, Inc.’s (the “Company”) responses:
Amendment No. 1 to Form S-1
Description of Securities
Forum of Adjudication of Disputes, page
1. We note your response to our prior comment 1 and reissue in part. Your forum selection provision identifies a Nevada state court as the exclusive forum for certain litigation, including and “derivative action.” We note from your revise disclosure that this provision applies to claims arising under the Exchange Act. Please note that Section 27 of the Exchange Act created exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Please revise the prospectus to clarify, it true, that the company does not intend for the exclusive forum provision to apply to Exchange Act claims.
RESPONSE: On page 91 we have revised the prospectus to clarify that the company does not intend for the exclusive forum provision to apply to Exchange Act claims.
The Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of the disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Relmada Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Relmada Therapeutics, Inc.
880 Third Avenue, 12th Floor
New York, NY 10022
October 17, 2019
VIA EDGAR
Tonya K. Aldave
Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re:
Relmada Therapeutics, Inc.
Amendment No. 1 to Registration Statement on Form S-l
Filed October 11, 2019
File No. 333-233228
Dear Ms. Aldave:
We are in receipt of your comment letter dated
October 16, 2019 regarding the above referenced filing. As requested in your letter, we have provided responses to the questions
raised by the staff. For your convenience, the matters are listed below, followed by Relmada Therapeutics, Inc.’s (the “Company”)
responses:
Amendment No. 1 to Form S-1
Description of Securities
Forum of Adjudication of Disputes, page
91
1.
We note your response to our prior comment 1 and reissue in part. Your forum selection provision identifies a Nevada state court as the exclusive forum for certain litigation, including and “derivative action.” We note from your revise disclosure that this provision applies to claims arising under the Exchange Act. Please note that Section 27 of the Exchange Act created exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Please revise the prospectus to clarify, it true, that the company does not intend for the exclusive forum provision to apply to Exchange Act claims.
RESPONSE:
On page 91 we have revised the prospectus to clarify that the company does not intend for the exclusive forum provision to apply to Exchange Act claims.
The Company acknowledges that
the Company and its management are responsible for the accuracy and adequacy of the disclosures, notwithstanding any review, comments,
action or absence of action by the staff.
Sincerely,
Relmada Therapeutics, Inc.
By:
/s/ Sergio Traversa
Sergio Traversa
Chief Executive Officer